Biomarker Validation Following Sargramostim Treatment in Parkinson's Disease
A Phase 1, Open-label Study to Validate Treatment-induced Biomarkers Following Sargramostim Treatment in Parkinson's Disease
Sponsor: Partner Therapeutics, Inc.
A PHASE1 clinical study on Parkinson's Disease and Parkinsonism, this trial is completed. The trial is conducted by Partner Therapeutics, Inc. and has accumulated 9 data snapshots since 2023. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE1
-
Dec 2024 — Dec 2025 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Sep 2024 — Dec 2024 [monthly]
Active Not Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1
▶ Show 4 earlier versions
-
Dec 2023 — Jun 2024 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Nov 2023 — Dec 2023 [monthly]
Recruiting PHASE1
Status: Active Not Recruiting → Recruiting
-
Jul 2023 — Nov 2023 [monthly]
Active Not Recruiting PHASE1
Status: Not Yet Recruiting → Active Not Recruiting
-
Feb 2023 — Jul 2023 [monthly]
Not Yet Recruiting PHASE1
First recorded
Jan 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Partner Therapeutics, Inc.
- University of Nebraska
For direct contact, visit the study record on ClinicalTrials.gov .